- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00465647
An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain (Palladone)
A Multi-center, Open-label, Dose Titration Study Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Hydromorphone Oral Solution in Subjects From 28 Days to 16 Years of Age, Who Require Opioid Analgesics for Postoperative Pain
Обзор исследования
Подробное описание
Hydromorphone is an opioid analgesic that has been used for decades as an alternative to morphine in the treatment of moderate to severe malignant and nonmalignant pain. Only a small number of analgesics have been studied in children. The benefits to the subjects include contribution of knowledge that will provide for appropriate dosing regimen recommendations for future pediatric subjects.
Treatment consisted of both parenteral and oral hydromorphone. For up to 48 hours immediately following surgery, subjects were administered hydromorphone by IV PCA pump. Dosing with the oral hydromorphone HCl began when the subject was ready to take clear oral liquid. Subjects were administered oral hydromorphone HCl every 6 hours for up to 9 doses. The investigator determined the timing of the first dose based on each subject's clinical condition.
The duration of the treatment phase was up to 102 hours (up to 48 hours for the Parenteral Treatment Period and up to 54 hours for the Oral Treatment Period).
Efficacy was based on the oral hydromorphone treatment. Adverse events were collected for both the oral and parenteral treatments.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 4
Контакты и местонахождение
Места учебы
-
-
Arkansas
-
Little Rock, Arkansas, Соединенные Штаты, 72202
- Arkansas Children's Hospital
-
-
California
-
Orange, California, Соединенные Штаты, 92868
- Children's Hospital of Orange County - Pediatric Subspecialty
-
Stanford, California, Соединенные Штаты, 94305
- Stanford University Medical Center
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80218
- The Children's Hospital
-
-
Connecticut
-
New Haven, Connecticut, Соединенные Штаты, 06510
- Yale-New Haven Children's Hospital
-
-
Florida
-
Miami, Florida, Соединенные Штаты, 33136
- Jackson Memorial Hospital
-
-
Iowa
-
Iowa City, Iowa, Соединенные Штаты, 52242
- University of Iowa Hospitals and Clinics
-
-
Missouri
-
St. Louis, Missouri, Соединенные Штаты, 63104
- Saint Louis University - Department of Neurology and Psychiatry
-
-
North Carolina
-
Chapel Hill, North Carolina, Соединенные Штаты, 27599-7221
- The University of North Carolina - CH
-
Durham, North Carolina, Соединенные Штаты, 27710
- Duke University Medical Center
-
-
Ohio
-
Akron, Ohio, Соединенные Штаты, 44308
- Children's Hospital Medical Center of Akron
-
-
Texas
-
Dallas, Texas, Соединенные Штаты, 75235
- Children's Medical Center
-
Houston, Texas, Соединенные Штаты, 77030
- Texas Children's Hospital / Baylor College of Medicine
-
Houston, Texas, Соединенные Штаты, 77030
- The University of Texas, Health Sciences Center at Houston
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Pediatric subjects aged 28 days to 16 years,
- Prospective subjects anticipated to have postoperative pain requiring oral opioid analgesics for at least 24 hours (up to 48 hours) following postoperative parenteral analgesia (up to 48 hours),
- Prospective subjects have received no more than a total of 7 doses of opioids in the 30 days prior to surgery.
Exclusion Criteria:
- Prospective subjects with clinically significant hepatic or renal dysfunction and impaired cardiac and/or respiratory reserve,
- Prospective subjects who have received opioid analgesic therapy other than hydromorphone or morphine sulfate during the up to 48-hour postoperative period prior to administration of first dose of oral hydromorphone,
- Prospective subjects who have received regional anesthetic blockade OR analgesic treatment with nonopioid medication within 6 hours prior to administration of first dose of oral hydromorphone.
Other protocol-specific inclusion/exclusion criteria may apply.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Экспериментальный: ≥ 28 Days to < 13 Months
infant and toddler
|
Oral hydromorphone solution dosed every 6 hours up to 9 doses.
Dose is determined based on the expected weight range for each age group.
Другие имена:
|
Экспериментальный: ≥ 13 months to < 5 years
young child
|
Oral hydromorphone solution dosed every 6 hours up to 9 doses.
Dose is determined based on the expected weight range for each age group.
Другие имена:
|
Экспериментальный: ≥ 5 years to < 12 years
older child
|
Oral hydromorphone solution dosed every 6 hours up to 9 doses.
Dose is determined based on the expected weight range for each age group.
Другие имена:
|
Экспериментальный: ≥ 12 years to < 17 years
adolescent
|
Oral hydromorphone solution dosed every 6 hours up to 9 doses.
Dose is determined based on the expected weight range for each age group.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Population Pharmacokinetic/Pharmacodynamic (PK/PD) Model for Hydromorphone: Clearance (Cl)
Временное ограничение: A maximum of 9 oral hydromorphone doses with potentially up to 54 hours duration.
|
Model was built using sparse blood samples: Sampling times: immediately predose, and between 0.25-0.75, 1-3, and 4-6 hours postdose for the first 2 doses of oral hydromorphone: predose for each dose of oral hydromorphone HCl thereafter; and at the end of study. Efficacy was based on Oral treatment only. |
A maximum of 9 oral hydromorphone doses with potentially up to 54 hours duration.
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Mean (SE) of Faces, Legs Activity, Cry, Consolability (FLACC) Pain Scores on Hydromorphone Alone (Oral/Supplemental) Over Time [Ages >=28 Days to <5 Years]
Временное ограничение: Immediately prior to first oral dose, up to 54 hours
|
There are 5 categories in this pediatric pain measurement: face, legs, activity, cry, and consolability.
Responses in each category are scored between 0 and 2 (0 = normal, relaxed to 2 = upset, agitated), for a maximum total score of 10.
The FLACC scale was used for children under the age of 3 years and older children who have limited verbal skills.
|
Immediately prior to first oral dose, up to 54 hours
|
Mean (SE) of Faces Pain Scale-Revised (FPS-R) [Ages >= 5 Years-< 12 Years] Pain Scores on Hydromorphone Alone (Oral/Supplemental)Over Time
Временное ограничение: Immediately prior to first oral dose with potentially up to 54 hours duration.
|
Faces Pain Scale-Revised (FPS-R) consists of 6 facial expressions.
Each face is 25 x 35 mm with 13 mm between faces.
Each subject was asked to point to the face that reflected his or her pain.
The end points are 0 = no pain and 10 = very much pain.
The FPS-R scale was used for children over the age of 5 up to 12 years who have appropriate verbal skills.
|
Immediately prior to first oral dose with potentially up to 54 hours duration.
|
Mean (SE) of Visual Analog Scale (VAS) [Ages 12-16] Pain Scores on Hydromorphone Alone (Oral/Supplemental) Over Time
Временное ограничение: Immediately prior to first oral dose, up to 54 hours
|
The Visual Analog Scale (VAS), a 10-cm Color Analog Scale anchored by the descriptors of 0 = "no pain" and 10 = "most pain," was used by children ≥ 12 years of age.
|
Immediately prior to first oral dose, up to 54 hours
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Gregory B. Hammer, MD, Stanford University
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- HMP4009
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Hydromorphone
-
Fujian Cancer HospitalЗавершенный
-
Alza Corporation, DE, USAЗавершенный
-
Alza Corporation, DE, USAЗавершенный